These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9915281)

  • 1. Neocytolysis: from outer space to the dialysis unit.
    Means RT
    Am J Kidney Dis; 1999 Jan; 33(1):140-1. PubMed ID: 9915281
    [No Abstract]   [Full Text] [Related]  

  • 2. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 3. Neocytolysis contributes to the anemia of renal disease.
    Rice L; Alfrey CP; Driscoll T; Whitley CE; Hachey DL; Suki W
    Am J Kidney Dis; 1999 Jan; 33(1):59-62. PubMed ID: 9915268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 5. The modality of dialysis treatment: does it influence the response to erythropoietin treatment?
    Locatelli F; Del Vecchio L; Andrulli S
    Nephrol Dial Transplant; 2001 Oct; 16(10):1971-4. PubMed ID: 11572880
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT; Sherwood RA; Hillis A; Peters TJ
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure.
    Ohyashiki JH; Fujieda H; Ohyashiki K; Toyama K
    Am J Hematol; 1991 Jun; 37(2):141-2. PubMed ID: 2069164
    [No Abstract]   [Full Text] [Related]  

  • 9. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
    Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating levels of thrombopoietin and erythropoietin in hemodialysis patients.
    Otsubo Y; Nitta K; Otsubo S; Kimata N; Miwa N; Watanabe Y; Uchida K; Kawashima A; Yumura W; Akiba T; Nihei H
    Acta Haematol; 2003; 109(4):209-11. PubMed ID: 12853697
    [No Abstract]   [Full Text] [Related]  

  • 13. [Review of the scientific evidence of the efficiency of erythropoietin use].
    García-Altés A; Puig-Junoy J
    Med Clin (Barc); 2006 Sep; 127(11):415-20. PubMed ID: 17020686
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum immunoreactive erythropoietin in patients with end stage renal disease.
    Gimenez LF; Watson AJ; Spivak JL
    Prog Clin Biol Res; 1990; 352():493-504. PubMed ID: 2402519
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
    Gallieni M
    Int J Artif Organs; 1998 Nov; 21(11):681-6. PubMed ID: 9894741
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.
    Pollok M; Bommer J; Gurland HJ; Koch KM; Schoeppe W; Scigalla P; Baldamus CA
    Contrib Nephrol; 1989; 76():201-11; discussion 212-8. PubMed ID: 2684523
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 18. [The abnormalities of blood cells in chronic kidney failure with long-term dialysis].
    Narita M; Shibata A
    Nihon Rinsho; 1992 Jan; 50 Suppl():763-70. PubMed ID: 1578764
    [No Abstract]   [Full Text] [Related]  

  • 19. Haemoglobin concentrations in chronic kidney disease.
    Steinbrook R
    Lancet; 2006 Dec; 368(9554):2191-3. PubMed ID: 17189015
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of angiotensin-converting enzyme inhibitors on anemia in hemodialyzed patients.
    Teruel JL; Fernandez Juarez G; Marcen R; Nogueira J; Ortuño J
    Nephron; 1996; 73(1):113. PubMed ID: 8742977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.